Welcome to our dedicated page for ESDA news (Ticker: ESDA), a resource for investors and traders seeking the latest updates and insights on ESDA stock.
Edesa Biotech, Inc. (ESDA) is a clinical-stage biopharmaceutical company pioneering treatments for inflammatory and immune-related conditions. This dedicated news hub provides investors and healthcare professionals with timely updates on ESDA's innovative drug development programs, including monoclonal antibody therapies and topical treatments targeting complex disorders like ARDS and vitiligo.
Access verified information about clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection features press releases on investigational new drug applications, government-funded study participation, and pipeline advancements in immune modulation therapies. All content undergoes rigorous verification to ensure accuracy and relevance.
Key focus areas include updates on ESDA's lead candidate EB05 for respiratory distress, anti-CXCL10 developments for autoimmune conditions, and sPLA2 inhibitor research for dermatological applications. Stay informed about critical FDA interactions and trial phase transitions through comprehensive coverage of the company's scientifically driven initiatives.
Bookmark this page for direct access to ESDA's official communications and third-party analyses. Regularly updated content ensures you maintain current awareness of the company's position in the competitive biopharma landscape without promotional bias.
Edesa Biotech (Nasdaq: ESDA) reported fiscal Q3 2024 results and provided a business update. Key highlights include:
- EB05 (paridiprubart) selected for U.S. government-funded ARDS study
- Plans to advance vitiligo and pulmonary fibrosis programs
- Q3 net loss of $1.7 million ($0.52 per share) vs $2.0 million ($0.68 per share) in Q3 2023
- 9-month net loss of $5.2 million ($1.64 per share) vs $6.7 million ($2.37 per share) in 2023
- Cash and equivalents of $2.0 million as of June 30, 2024
- $0.3 million received in government funding post-quarter end
- Unused $10.0 million revolving credit agreement available
Management views the government ARDS study as a potential value-creation opportunity and plans to focus on advancing other pipeline programs.
